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Mycobacterial disease overlooked in a frail
diabetic male treated for pneumonia
Aydin Tavakoli, MSc, M.D.; Glenn V. Dregansky, D.O.
Purpose
Mycobacterial disease is treatable and its spread is preventable. Even in the United
States its’ insidious presentation and low incidence, can be overlooked when
practitioners address pulmonary disease. We present a case of mycobacterial
illness mistakenly treated as severe pneumonia.
Consideration for tuberculosis (TB) & non-tuberculous mycobacterial disease (NTM)
1. Data for spread of TB/ NTM mycobacterial disease in the US:
•The WHO estimates that 1/3 of the world’s population is infected with TB with a
resurgence in both TB and NTM.
•TB low incidence in US but risk factors (RFs), while spread of NTM disease in the US
is unknown.
2. Diagnostic criteria has become more lenient and with expansion of specific
radiological criteria more cases of TB diagnosed and treated1

CASE REPORT
Patient description:
- 43 year old Caucasian male with poorly controlled type 1 diabetes
- A1c 9.1%, with considerable neuropathy, non smoker, no drug use
- 1 month history of cough, weakness, night sweats/chills, weight loss,
severe dyspnea on exertion
- Incarceration, 10 yrs ago (TB skin test positive with negative CXR)

Principles:
•Identify/Screen patients at high risk for TB/ latent TB infection (LTBI)
•Screening modality in individuals with poor follow up
•Differential in immunocompromised patient must be broad
•Populations in TB endemic areas are known to have concomitant
TB/pneumonia, in the low endemic areas such as the US, these cases are
insidious5

Presented to ED in DKA. He was treated in ICU for euglycemia and his
pulmonary disease was characterized as a bacterial pneumonia.
- respiratory infectious disease panel was negative and he was treated with
broad spectrum antibiotics and discharged.

What we’ve learned: someone that has symptoms and risk factors must be
screened for mycobacterial disease

Hospital follow up a week post discharge, complains of continued dyspnea on
exertion and weakness. A careful examination of imaging report and history
taking consisted with a timely screening for TB.

3. Awareness of risk factors for mycobacterial disease (selected few4)
Immunocompromised Host
Environmental Factors
- AIDS
- incarceration
- Steroid treatment
- homelessness
- Carcinoma
- occupational exposure
- Transplant recipients
- Children
4. High risk progression latent TB infection to TB (selected risk factors)2
- HIV
- immunocompromised (Diabetes mellitus, steroid therapy)
- malignancies
- infants and children < 4 years of age
- body weight ≥ 10% below ideal body weight

Picture 1 and Picture 2 –CT chest with
contrast coronal (left), and axial (above).
Strongly suggestive of tuberculosis. Mediastinal
hilar adenopathy, apical infiltrates. Notable of a
military infiltrative pattern.

QuantiFERON gold test (QFT) was positive and our patient was admitted again,
this time to our isolation inpatient service for evaluation.
- His acid fast bacillus smear being positive, he was started on rifampin, isoniazid,
pyrazinamide, ethambutol (RIPE) therapy. He was discharged after three negative
sputum smears on the same therapy with cultures pending final characterization.
On hospital follow up, he was continuing his RIPE therapy. His blood glucoses
were not well controlled with improvement in his respiratory status as he was
ambulating with less dyspnea. No chills, fevers, night sweats. Moderate weight
gain.

Figure 1: Resident of any type of correctional facility at the time of TB
diagnosis. Total number of cases have dropped by percentage of total cases from
correctional facilities has risen.

Figure 2: Total number of reported U.S. TB cases and the associated rates
for each of the past 6 years. Rate = cases/100,000 population. Rate has not
decreased in last 2 years.

Discussion

Our patient was lost to subsequent follow up. He had not been seen again by our
ID colleagues.

Future considerations
This report documents a common treatment algorithm, based on a differential
focused on typical culprits for pulmonary infection. Latent mycobacterial
infections in our community do exist, and can lead to fulminant TB especially in
individuals who are immunocompromised and uncontrolled diabetics.
Mycobacterial risk in these populations should be assessed. Screening tests, even
in non-compliant individuals are easily obtainable. A focus should be placed on
identifying patients at risk for exposure to TB and providing diagnosis and
treatment for latent infection or active disease.
Our residency program works out of a Federally Qualified Health Center, where
our population is high risk for LTBI. Risk factors include: residing in shelters,
homelessness, higher rates of intravenous drug use, chronic conditions, and/or
history of imprisonment. Many of these factors contribute to
low rates of follow-up for screening with the tuberculin skin test.
Ideal State: Identifying and screening high-risk patients with no previous testing or
prior negative test results with the QFT. This is a blood test which does not require
follow-up for results. Use a symptoms-based questionnaire for patients with
known LTBI to monitor progression to active disease. QFT could be administered
to those identified as high risk even with no previous testing or prior negative test
results. As these tests result, evaluation with a chest X-ray would stratify our
groups to either further evaluate for latent mycobacterial infections or to treat
based on positive chest X-ray. Educating all providers who care for these patients
on whom to screen for TB and how to follow-up on positive results. Outcome
measure would include: TB screening tests, follow up imaging, and treatment if
indicated for LTBI or active infections.
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